Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib in NSAID-Refractory Axial Spondyloarthritis
NCT03738956Phase 3Unknown
- Sponsor
- Globe Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tofacitinib in axial spondyloarthritis (axSpA), sponsored by Globe Pharmaceuticals. Primary endpoint: Assessment of Spondyloarthritis International Society 20 Response at 12 weeks. Status: unknown.
02
Drugs
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT03738956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03738956.